# US 2004/0082014 A1 · Method and test system for identifying substances which protect nerve cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0082014 A1
- Document ID: US20040082014A1
- Status: Published application
- Kind: A1
- Application number: 10/470,068
- Filed: 2003-12-12
- Published: 2004-04-29
- Earliest claimed: 2001-01-22
- Inventors: Michael Sendtner; Ulf Rudiger Rapp; Stefan Wiese
- Web page: https://patentgrep.com/patent/US20040082014A1

## CPC

- G01N 33/5091: {for testing the pathological state of an organism}
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12Q 1/6809: Methods for determination or identification of nucleic acids involving differential detection
- C12Q 1/6897: involving reporter genes operably linked to promoters
- G01N 33/5008: {for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics}
- G01N 33/5058: {Neurological cells}
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The invention relates to a method for identifying pharmacologically active ingredients which influence the function of cells in the central nervous system. The inventive method comprises the following steps: a) a sample is brought into contact with at least one potential active ingredient, and b) the activity of Raf, especially B-Raf, in the sample is determined.

## Claims

### Claim 1

A method for identifying pharmacologically active ingredients which influence the function of cells in a central nervous system, comprising the following steps:
a) a sample is brought into contact with at least one potential active ingredient, and
b) the activity of B-Raf in the sample is determined.

### Claim 2 (depends on 1)

A method according to claim 1, wherein the sample contains at least one cell, at least one cell extract, at least one protein mixture and/or one mixture containing B-Raf, in particular activated B-Raf, or a part thereof.

### Claim 3 (depends on 2)

A method according to claim 2, wherein the cell is a glial cell; a neuronal cell, for instance a sensor, sympathic or motor neuronal cell; a neuronal stem cell; a neuron, in particular a cholinergic neuron of the basal forebrain, a dopaminergic nerve cell of the midbrain, a granule cell, a Purkinje cell of the cerebellum or the hippocampus; a retinal ganglion cell or a photoreceptor.

### Claim 4 (depends on 2, 3)

A method according to one of claims 2 or 3, wherein the cell has a reduced B-Raf activity or no B-Raf activity at all.

### Claim 5 (depends on 1, 2, 3, 4)

A method according to one of claims 1 to 4, wherein the activity of B-Raf in the cell is determined by the change of the survival rate of the cell.

### Claim 6 (depends on 1, 2, 3, 4)

A method according to one of claims 1 to 4, wherein the activity of B-Raf in the sample is directly or indirectly determined by the amount of the B-Raf protein, the amount of the nucleic acids coding for B-Raf and/or the enzymatic activity of B-Raf.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

A method according to one of claims 1 to 6, wherein in a further step the activity of IAP-1, IAP-2, x-IAP and/or survivin is determined.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

A method according to one of claims 1 to 7, wherein in a further step the pharmacologically active ingredient is isolated.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

An active ingredient identified by the method according to one of claims 1 to 8.

### Claim 10

A method for the in vitro analysis of the function of cells of the central nervous system, characterized by that the activity of B-Raf, IAP-1, IAP-2, x-IAP and/or survivin in the cells and/or cell extracts is determined.

### Claim 11

A diagnostic substance for the in vitro analysis of the function of cells of the central nervous system, comprising at least one agent for the detection of the activity of B-Raf, IAP-1, IAP-2, x-IAP and/or survivin.

### Claim 12

A test system for identifying pharmacologically active ingredients which influence the function of cells in a central nervous system, comprising:
a) at least one sample; and
b) al least one agent for determining the B-Raf activity in the sample.

### Claim 13

A drug for treating diseases occurring with a disturbance of the function of the cells of the central nervous system, containing B-Raf and if applicable suitable auxiliary and additional substances.

### Claim 14 (depends on 13)

A drug according to claim 13, wherein the disturbance of the function of the cells of the central nervous system is characterized by a reduction of the survival rate of the cells.

### Claim 15 (depends on 13, 14)

A drug according to claim 13 or 14, wherein B-Raf is included in a vector.
